Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Tamsulosin Hydrochloride

FDA-approved product (capsule, oral), marketed as Flomax, Tamsulosin Hydrochloride.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Tamsulosin Hydrochloride
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Benign prostatic hyperplasia
  • Prostate carcinoma

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Alpha-adrenoreceptor antagonists
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA28.3% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli31.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae21.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis73.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Tamsulosin Hydrochloride in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Tamsulosin Hydrochloride with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Uroselective Alpha-1-Antagonist to Reduce the Incidence and Duration of Postoperative Urinary Retention Following Spine Surgery

    NCT07174349 · start 2026-10-01

    Registered record
    Registry ID
    NCT07174349
    Conditions
    Urinary Retention Postoperative
    Interventions
    Uroselective alpha-1-adrenergic receptor antagonist; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2026-10-01
    Completion
    2028-12-31
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionUrinary Retention Postoperative
    InterventionUroselective alpha-1-adrenergic receptor antagonist; Placebo
    PhasePhase 4
    Registry statusRecruiting

  • Tamsulosin Monotherapy Versus Combination Therapy With Tadalafil (2.5 mg vs 5 mg) in Managing Male LUTS Secondary to BPH

    NCT07722884 · start 2026-07-01

    Registered record
    Registry ID
    NCT07722884
    Conditions
    Safety; Efficacy; Tamsulosin; Monotherapy; Tadalafil; Lower Urinary Tract Symptoms; Benign Prostatic Hyperplasia
    Interventions
    Tamsulosin 0.4 mg + Tadalafil 2.5 mg; Tamsulosin 0.4 mg + Tadalafil 5 mg; Tamsulosin 0.4 mg
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Recruiting
    Start
    2026-07-01
    Completion
    2027-01-01
    Enrolment
    90

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSafety; Efficacy; Tamsulosin; Monotherapy +3 more
    InterventionTamsulosin 0.4 mg + Tadalafil 2.5 mg; Tamsulosin 0.4 mg + Tadalafil 5 mg; Tamsulosin 0.4 mg
    PhaseNot applicable
    Registry statusRecruiting

  • Efficacy of Acupuncture for Postoperative Urinary Retention Following Radical Hysterectomy for Cervical Cancer

    NCT07711977 · start 2026-07

    Registered record
    Registry ID
    NCT07711977
    Conditions
    Postoperative Urinary Retention (POUR)
    Interventions
    Acupuncture; Sham acupuncture
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Not yet recruiting
    Start
    2026-07
    Completion
    2028-12-31
    Enrolment
    324

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPostoperative Urinary Retention (POUR)
    InterventionAcupuncture; Sham acupuncture
    PhaseNot applicable
    Registry statusNot yet recruiting

  • A Study to Evaluate the Safety and Pharmacokinetics of AD-116 and AD-1161 in Healthy Adult Male Subjects

    NCT07444385 · start 2026-02-26

    Registered record
    Registry ID
    NCT07444385
    Conditions
    Benign Prostatic Hyperplasia
    Interventions
    AD-116, AD-1161
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Recruiting
    Start
    2026-02-26
    Completion
    2026-05-08
    Enrolment
    44

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBenign Prostatic Hyperplasia
    InterventionAD-116, AD-1161
    PhasePhase 1
    Registry statusRecruiting

  • Standard Versus Double Alpha Blockers Treatment for Symptomatic Benign Prostatic Obstruction

    NCT07815379 · start 2025-10-12

    Registered record
    Registry ID
    NCT07815379
    Conditions
    BPH (Benign Prostatic Hyperplasia)
    Interventions
    alpha blocker monotherapy Tamsulosin; alpha blockers Tamsulosin and Silodosin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Active not recruiting
    Start
    2025-10-12
    Completion
    2026-11
    Enrolment
    140

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBPH (Benign Prostatic Hyperplasia)
    Interventionalpha blocker monotherapy Tamsulosin; alpha blockers Tamsulosin and Silodosin
    PhasePhase 4
    Registry statusActive not recruiting

  • Study of Tamsulosin, Solifenacin and Mirabegron in Alleviating Ureteral Stent-related Symptoms

    NCT06803030 · start 2025-08-30

    Registered record
    Registry ID
    NCT06803030
    Conditions
    Ureteral Stent-Related Symptom
    Interventions
    Tamsulosin Hydrochloride 0.4 mg; Solifenacin Succinate 5 mg; Mirabegron 25 mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2025-08-30
    Completion
    2026-12-31
    Enrolment
    189

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionUreteral Stent-Related Symptom
    InterventionTamsulosin Hydrochloride 0.4 mg; Solifenacin Succinate 5 mg; Mirabegron 25 mg
    PhasePhase 3
    Registry statusRecruiting

  • Medical Stone Expulsive Therapy for Acutely Obstructed Ureteric Calculi

    NCT05977647 · start 2024-09-01

    Registered record
    Registry ID
    NCT05977647
    Conditions
    Ureteric Stone of Lower Third of Ureter
    Interventions
    Tamsulosin Oral Capsule
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2024-09-01
    Completion
    2025-06-30
    Enrolment
    240

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionUreteric Stone of Lower Third of Ureter
    InterventionTamsulosin Oral Capsule
    PhasePhase 4
    Registry statusCompleted

  • Comparing Tamsulosin and Solifenacin for Relieving Double J Stent Symptoms: Using the USSQ.

    NCT07114848 · start 2024-06-13

    Registered record
    Registry ID
    NCT07114848
    Conditions
    Ureteral Stent-Related Symptom; Alpha Blocker; Anticholinergics; Ureter Calculi
    Interventions
    Tamsulosin; solifenacin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2024-06-13
    Completion
    2025-03-30
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionUreteral Stent-Related Symptom; Alpha Blocker; Anticholinergics; Ureter Calculi
    InterventionTamsulosin; solifenacin
    PhasePhase 4
    Registry statusCompleted

  • Can Acupoint Low Intensity Shockwave Therapy Improve Bladder Voiding Efficiency

    NCT06020963 · start 2023-08-11

    Registered record
    Registry ID
    NCT06020963
    Conditions
    Detrusor Underactivity
    Interventions
    Low Intensity Shockwave Therapy (LiSWT); Tamsulosin
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2023-08-11
    Completion
    2024-12-31
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDetrusor Underactivity
    InterventionLow Intensity Shockwave Therapy (LiSWT); Tamsulosin
    PhaseNot applicable
    Registry statusUnknown

  • Adding Desmopressin to Tamsulosin for Treatment of BPH

    NCT05945420 · start 2023-07-20

    Registered record
    Registry ID
    NCT05945420
    Conditions
    Nocturnal Polyurea in Patients With BPH
    Interventions
    Desmopressin Acetate; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2023-07-20
    Completion
    2024-02-10
    Enrolment
    160

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNocturnal Polyurea in Patients With BPH
    InterventionDesmopressin Acetate; Placebo
    PhasePhase 4
    Registry statusUnknown

  • The Efficacy and Safety of Qianweitai (Silodosin Capsule) Versus Tamsulosin in the Treatment of BPH

    NCT07134907 · start 2022-07-18

    Registered record
    Registry ID
    NCT07134907
    Conditions
    BPH (Benign Prostatic Hyperplasia)
    Interventions
    Silodosin; Tamsolusin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2022-07-18
    Completion
    2024-07-09
    Enrolment
    110

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBPH (Benign Prostatic Hyperplasia)
    InterventionSilodosin; Tamsolusin
    PhasePhase 4
    Registry statusCompleted

  • (Phosphodiesterase 5 Inhibitors & α-blockers): Single Versus Combined Therapy in Benign Prostatic Hyperplasia

    NCT05236634 · start 2022-05-01

    Registered record
    Registry ID
    NCT05236634
    Conditions
    Benign Prostatic Hyperplasia
    Interventions
    Phosphodiesterase 5 Inhibitors; Alpha Blockers; Combined Alpha Blockers and Phosphodiesterase 5 Inhibitors
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2022-05-01
    Completion
    2024-06-30
    Enrolment
    120

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBenign Prostatic Hyperplasia
    InterventionPhosphodiesterase 5 Inhibitors; Alpha Blockers; Combined Alpha Blockers and Phosphodiesterase 5 Inhibitors
    PhaseNot applicable
    Registry statusUnknown

  • Tamsulosin Assisted Ureteral Access Sheath Insertion

    NCT05197088 · start 2022-01-09

    Registered record
    Registry ID
    NCT05197088
    Conditions
    Renal Stone; Retrograde Intrarenal Surgery; Urolithiasis
    Interventions
    Tamsulosin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2022-01-09
    Completion
    2023-07-31
    Enrolment
    110

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRenal Stone; Retrograde Intrarenal Surgery; Urolithiasis
    InterventionTamsulosin
    PhasePhase 3
    Registry statusUnknown

  • Treatment of BPH With CO2 Serenoa +PEA as Monotherapy or in Combination With Tamsulosin: ProSeRePEA Trial

    NCT06181175 · start 2021-10-01

    Registered record
    Registry ID
    NCT06181175
    Conditions
    Benign Prostatic Hyperplasia; Urinary Obstruction; Lower Urinary Tract Symptoms
    Interventions
    PEAPROSTIL 600 + Tamsulosin 0.4 mg; Tamsulosin 0.4 mg; PEAPROSTIL 600 mg
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2021-10-01
    Completion
    2025-04-30
    Enrolment
    250

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBenign Prostatic Hyperplasia; Urinary Obstruction; Lower Urinary Tract Symptoms
    InterventionPEAPROSTIL 600 + Tamsulosin 0.4 mg; Tamsulosin 0.4 mg; PEAPROSTIL 600 mg
    PhaseNot applicable
    Registry statusUnknown

  • Deprescribing Tamsulosin in Older Men

    NCT05415748 · start 2021-09-18

    Registered record
    Registry ID
    NCT05415748
    Conditions
    Benign Prostatic Hyperplasia; Lower Urinary Tract Symptoms
    Interventions
    Tamsulosin; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2021-09-18
    Completion
    2022-07-22
    Enrolment
    31

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBenign Prostatic Hyperplasia; Lower Urinary Tract Symptoms
    InterventionTamsulosin; Placebo
    PhasePhase 4
    Registry statusCompleted